par Neyrinck, Audrey M.;Rodriguez, Julie;Zhang, Zhengxiao;Seethaler, Benjamin;Sánchez, Cándido Robles;Roumain, Martin;Hiel, Sophie;Bindels, Laure B.;Cani, Patrice D.;Paquot, Nicolas;Cnop, Miriam ;Nazare, Julie Anne;Laville, Martine;Muccioli, Giulio Giulio;Bischoff, Stephan C.;Walter, Jens;Thissen, Jean Paul;Delzenne, Nathalie Maria
Référence European journal of nutrition, 60, 6, page (3159-3170)
Publication Publié, 2021-09-01
Référence European journal of nutrition, 60, 6, page (3159-3170)
Publication Publié, 2021-09-01
Article révisé par les pairs
Résumé : | Abstract Purpose Inulin-type fructans (ITF) are prebiotic dietary fibre (DF) that may confer beneficial health effects, by interacting with the gut microbiota. We have tested the hypothesis that a dietary intervention promoting inulin intake versus placebo influences fecal microbial-derived metabolites and markers related to gut integrity and inflammation in obese patients. Methods Microbiota (16S rRNA sequencing), long- and short-chain fatty acids (LCFA, SCFA), bile acids, zonulin, and calprotectin were analyzed in fecal samples obtained from obese patients included in a randomized, placebo-controlled trial. Participants received either 16 g/d native inulin (prebiotic n = 12) versus maltodextrin (placebo n = 12), coupled to dietary advice to consume inulin-rich versus inulin-poor vegetables for 3 months, in addition to dietary caloric restriction. Results Both placebo and prebiotic interventions lowered energy and protein intake. A substantial increase in Bifidobacterium was detected after ITF treatment ( q = 0.049) supporting our recent data obtained in a larger cohort. Interestingly, fecal calprotectin, a marker of gut inflammation, was reduced upon ITF treatment. Both prebiotic and placebo interventions increased the ratio of tauro-conjugated/free bile acids in feces. Prebiotic treatment did not significantly modify fecal SCFA content but it increased fecal rumenic acid, a conjugated linoleic acid ( cis -9, trans -11 CLA) with immunomodulatory properties, that correlated notably to the expansion of Bifidobacterium ( p = 0.031; r = 0.052). Conclusions Our study demonstrates that ITF-prebiotic intake during 3 months decreases a fecal marker of intestinal inflammation in obese patients. Our data point to a potential contribution of microbial lipid-derived metabolites in gastro-intestinal dysfunction related to obesity. ClinicalTrials.gov Identifier NCT03852069 (February 22, 2019 retrospectively, registered). |